IP Library Granted Patent US 8,440,226
Granted Patent B2
US 8,440,226 · App. 13/526,375 · Granted May 14, 2013

Solvent/polymer solutions as suspension vehicles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,226
App. No.
13/526,375
Granted
May 14, 2013
Kind
B2
Abstract

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Claims (15)

1. A stable, nonaqueous suspension formulation, comprising:

a particle formulation comprising an active agent and an excipient, wherein the active agent comprises a peptide, polypeptide, or protein, and the excipient comprises methionine; and

a nonaqueous, single-phase vehicle consisting essentially of about 10% to about 90% (w/w) polyvinylpyrrolidone and about 90% to about 10% (w/w) benzyl benzoate, wherein the vehicle has a viscosity of between approximately 10,000 poise to approximately 20,000 poise measured at 37° C.

2. The suspension formulation of claim 1 , wherein the particle formulation comprises one or more additional excipients.

3. The suspension formulation of claim 2 , wherein the one or more additional excipients are selected from the group consisting of citrate buffer, sucrose, succinate, and dextran.

4. The suspension formulation of claim 2 , wherein the one or more additional excipients comprise sucrose and citrate buffer.

5. The suspension formulation of claim 1 , wherein the single-phase vehicle consists essentially of about 25% to about 75% (w/w) polyvinylpyrrolidone and about 75% to about 25% (w/w) benzyl benzoate.

6. The suspension formulation of claim 1 , wherein the particle formulation is formed by lyophilization, spray-drying, or freeze-drying.

7. The suspension formulation of claim 1 , wherein the particle formulation is present in the suspension formulation in a range from approximately 0.1 to 50 wt %.

8. The suspension formulation of claim 1 , wherein the particle formulation is present in the suspension formulation in a range from approximately 3 to 12 wt %.

9. A method of making the suspension formulation of claim 1 , the method comprising

blending the polyvinylpyrrolidone and benzyl benzoate to form the single-phase vehicle, wherein a vacuum is applied during blending to remove air bubbles; and

adding the particle formulation to form the suspension formulation.

10. The method of claim 9 , wherein the vacuum is between about −5 to about −10 Hg.

11. The method of claim 10 , further comprising increasing the vacuum after the polyvinylpyrrolidone is incorporated into the benzyl benzoate to about −30 Hg.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
Reel/Frame 052433/0001 →
RELEASE OF SECURITY INTEREST Recorded Jan 29, 2020
From: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 051739/0453 →
SECURITY INTEREST Recorded Oct 23, 2019
From: INTARCIA THERAPEUTICS, INC.
To: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT
Reel/Frame 050801/0267 →
SECURITY INTEREST Recorded Oct 9, 2019
From: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050673/0020 →
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2015
From: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 036942/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2015
From: ALZA CORPORATION
To: INTARCIA THERAPEUTICS INC.
Reel/Frame 035256/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: ROHLOFF, CATHERINE M.; CHEN, GUOHUA; LUK, ANDREW S.; AYER, RUPAL A.; HOUSTON, PAUL R.; DESJARDIN, MICHAEL A.; ZAMORA, PAULINE; LAM, STAN
To: ALZA CORPORATION
Reel/Frame 031769/0105 →
LICENSE AGREEMENT Recorded Dec 10, 2013
From: ALZA CORPORATION
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 031793/0475 →
SECURITY AGREEMENT Recorded Nov 14, 2012
From: INTARCIA THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029299/0678 →